Summary

Observational studies have suggested that spontaneously higher high-density lipoprotein cholesterol (HDL-C) levels are associated with lower cardiovascular (CV) risk; however, it is uncertain whether raising HDL-C by a pharmacologic approach reduces the risk. The objective of the Study of RO4607381 in Stable Coronary Heart Disease Patients With Recent Acute Coronary Syndrome [dal-OUTCOMES; NCT00658515; Schwartz GG et al. N Engl J Med 2012] was to compare the effects of dalcetrapib versus placebo in patients with recent acute coronary syndrome.